Upgrades
Downgrades
Initiations
- With a rating of Outperform, RBC Capital initiated coverage on ACADIA Pharmaceuticals Inc (NASDAQ:ACAD). The price target is set at $60.00 for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals earned ($0.38) in the second quarter, compared to ($0.51) in the year-ago quarter. ACADIA Pharmaceuticals's market cap stands at $5.5 billion. The stock has a 52-week-high of $44.85 and a 52-week-low of $14.01. ACADIA Pharmaceuticals's stock last closed at $35.99 per share.
- Berenberg initiated coverage on Agree Realty Corp (NYSE:ADC) with a Buy rating. The price target for Agree Realty is set at $82.00. For the second quarter, Agree Realty had an EPS of $0.74, compared to year-ago quarter EPS of $0.70. The total market value of Agree Realty's outstanding shares is at $3.0 billion. The stock has a 52-week-high of $76.23 and a 52-week-low of $50.72. Agree Realty's stock last closed at $73.12 per share.
- With a rating of Hold, Stifel initiated coverage on bluebird bio Inc (NASDAQ:BLUE). The price target is set at $109.00 for bluebird bio. In the second quarter, bluebird bio showed an EPS of ($3.55), compared to ($2.91) from the year-ago quarter. bluebird bio's market cap stands at $5.8 billion. The stock has a 52-week-high of $163.43 and a 52-week-low of $87.49. bluebird bio's stock last closed at $91.82 per share.
- With a rating of Outperform, Wells Fargo initiated coverage on Blackstone Group Inc (NYSE:BX). The price target is set at $60.00 for Blackstone Group. For the second quarter, Blackstone Group had an EPS of $0.45, compared to year-ago quarter EPS of $0.90. The total market value of Blackstone Group's outstanding shares is at $63.1 billion. The stock has a 52-week-high of $55.17 and a 52-week-low of $26.88. Blackstone Group's stock last closed at $48.86 per share.
- Stifel initiated coverage on Fate Therapeutics Inc (NASDAQ:FATE) with a Buy rating. The price target for Fate Therapeutics is set at $27.00. For the second quarter, Fate Therapeutics had an EPS of ($0.36), compared to year-ago quarter EPS of ($0.37). The total market value of Fate Therapeutics's outstanding shares is at $1.0 billion. The stock has a 52-week-high of $22.82 and a 52-week-low of $11.00. Fate Therapeutics's stock last closed at $15.53 per share.
- Stifel initiated coverage on Iovance Biotherapeutics Inc (NASDAQ:IOVA) with a Buy rating. The price target for Iovance Biotherapeutics is set at $27.00. In the second quarter, Iovance Biotherapeutics showed an EPS of ($0.38), compared to ($0.34) from the year-ago quarter. Iovance Biotherapeutics's market cap stands at $2.5 billion. The stock has a 52-week-high of $26.59 and a 52-week-low of $7.26. Iovance Biotherapeutics's stock last closed at $18.20 per share.
- Raymond James initiated coverage on WEX Inc (NYSE:WEX) with a Market Perform rating. WEX earned $2.28 in the second quarter, compared to $2.09 in the year-ago quarter. The current market cap for WEX is at $8.6 billion. The stock has a 52-week-high of $221.66 and a 52-week-low of $131.35. WEX's stock last closed at $202.02 per share.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
